In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ferring Pharmaceuticals

http://www.ferring.com

Latest From Ferring Pharmaceuticals

ContraFect’s Path Forward Gets Murky With Exebacase Trial Failure

The company said it would discontinue the Phase III trial of the MRSA drug for futility, leaving it with no major catalysts and an uncertain cash position.

Clinical Trials Business Strategies

Destiny Pharma Sees Potential For XF-73 In Oral Mucositis

A new research program exploring an additional indication for XF-73 will help the UK biotech's licensing discussions for the nasal gel.

Research & Development Clinical Trials

New Modalities Help Chinese Biotechs Win Investors’ Attention

Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.

China Financing

SIFI’s Parasitic Eye Infection Drug & Biosimilar Aflibercept Among Raft Of EU Filings

Polyhexanide, from SIFI, could become the first approved treatment for acanthamoeba keratitis, while aflibercept could become the first biosimilar version of Eylea in the EU.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • BioSurface Engineering Technologies, Inc. (BioSET)
    • Cytokine PharmaSciences, Inc. (Subsidiary: Controlled Therapeutics Ltd.)
    • Ferring Pharmaceuticals
    • FerGene
    • Rebiotix, Inc.
UsernamePublicRestriction

Register